ReviewMedizinische Klinik (Munich, Germany : 1983)2009
[Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease].
Review in Medizinische Klinik (Munich, Germany : 1983), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
- Comparison of the coaxial circle circuit with the conventional circle circuit.The Eurasian journal of medicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is overwhelming evidence from large-scale placebo-controlled trials but also from epidemiologic COPD (chronic obstructive pulmonary disease) studies and meta-analyses supporting FEV(1) (forced expiratory volume in 1 s) as a strong diagnostic and prognostic marker that predicts future morbidity and mortality. Specifically, attenuation of reduced FEV(1) is a powerful indicator of successful medical intervention and vice versa. FEV(1) decline indicates an increasing risk for advanced disease stage eventually leading to further deterioration. However, it remains to be determined whether reducing the frequency of exacerbations or pharmacological improvement of FEV(1) can help to slow lung function decline and consequently improve clinical outcome in these patients. All in all, FEV(1) and its change over time are essential parameters in the assessment of COPD progression and efficacy of therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.